Abstract

Addictive substance use impairs cognitive flexibility, with unclear underlying mechanisms. The reinforcement of substance use is mediated by the striatal direct-pathway medium spiny neurons (dMSNs) that project to the substantia nigra pars reticulata (SNr). Cognitive flexibility is mediated by striatal cholinergic interneurons (CINs), which receive extensive striatal inhibition. Here, we hypothesized that increased dMSN activity induced by substance use inhibits CINs, reducing cognitive flexibility. We found that cocaine administration in rodents caused long-lasting potentiation of local inhibitory dMSN-to-CIN transmission and decreased CIN firing in the dorsomedial striatum (DMS), a brain region critical for cognitive flexibility. Moreover, chemogenetic and time-locked optogenetic inhibition of DMS CINs suppressed flexibility of goal-directed behavior in instrumental reversal learning tasks. Notably, rabies-mediated tracing and physiological studies showed that SNr-projecting dMSNs, which mediate reinforcement, sent axonal collaterals to inhibit DMS CINs, which mediate flexibility. Our findings demonstrate that the local inhibitory dMSN-to-CIN circuit mediates the reinforcement-induced deficits in cognitive flexibility.

Addictive substances may impair cognitive flexibility. Here the authors show that in rodents, increased activity of striatal direct-pathway medium spiny neurons (dMSNs) in response to cocaine inhibits cholinergic interneurons (CINs), reducing cognitive flexibility.

Details

Title
Drug reinforcement impairs cognitive flexibility by inhibiting striatal cholinergic neurons
Author
Gangal, Himanshu 1 ; Xie, Xueyi 2 ; Huang, Zhenbo 2 ; Cheng, Yifeng 2   VIAFID ORCID Logo  ; Wang, Xuehua 2 ; Lu, Jiayi 2 ; Zhuang, Xiaowen 2 ; Essoh, Amanda 2 ; Huang, Yufei 1 ; Chen, Ruifeng 3 ; Smith, Laura N. 1   VIAFID ORCID Logo  ; Smith, Rachel J. 4 ; Wang, Jun 5   VIAFID ORCID Logo 

 Texas A&M University Health Science Center, Department of Neuroscience and Experimental Therapeutics, School of Medicine, Bryan, USA (GRID:grid.412408.b); Texas A&M University, Institute for Neuroscience, College Station, USA (GRID:grid.264756.4) (ISNI:0000 0004 4687 2082) 
 Texas A&M University Health Science Center, Department of Neuroscience and Experimental Therapeutics, School of Medicine, Bryan, USA (GRID:grid.412408.b) 
 Texas A&M University Health Science Center, Department of Neuroscience and Experimental Therapeutics, School of Medicine, Bryan, USA (GRID:grid.412408.b); Texas A&M University, Interdisciplinary Faculty of Toxicology, College Station, USA (GRID:grid.264756.4) (ISNI:0000 0004 4687 2082) 
 Texas A&M University, Institute for Neuroscience, College Station, USA (GRID:grid.264756.4) (ISNI:0000 0004 4687 2082); Texas A&M University, Department of Psychological and Brain Sciences, College Station, USA (GRID:grid.264756.4) (ISNI:0000 0004 4687 2082) 
 Texas A&M University Health Science Center, Department of Neuroscience and Experimental Therapeutics, School of Medicine, Bryan, USA (GRID:grid.412408.b); Texas A&M University, Institute for Neuroscience, College Station, USA (GRID:grid.264756.4) (ISNI:0000 0004 4687 2082); Texas A&M University, Interdisciplinary Faculty of Toxicology, College Station, USA (GRID:grid.264756.4) (ISNI:0000 0004 4687 2082) 
Pages
3886
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2831684193
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.